HARBIN, China, Aug. 6 /PRNewswire-Asia-FirstCall/ -- Renhuang
Pharmaceuticals, Inc. (NYSE Amex: CBP) ("Renhuang" or the "Company"), a
developer, manufacturer and distributor of botanical products,
bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced
that on August 3, 20